Every batch of peptides from saiyanmed goes through a non-negotiable, multi-step verification process with Janoshik Analytical, an independent third-party laboratory based in the Czech Republic. The company does not rely on in-house testing or self-reported purity claims. Instead, each production lot is physically shipped to Janoshik’s facility, where it undergoes high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis. The results are published as openly verifiable Certificates of Analysis (CoAs) on the saiyanmed website, allowing any researcher to cross-reference the batch number, purity percentage, and molecular weight confirmation directly on Janoshik’s public database. This means you are not taking the company’s word for it — you are reading raw data from an accredited lab that has no financial stake in the outcome.
The testing protocol begins before the raw materials even enter production. SaiyanMed sources its peptide raw materials from GMP-compliant facilities in China and Europe, and each incoming shipment is sampled and sent to Janoshik for identity verification. If the raw material fails to meet the specified purity threshold — typically 98% or higher — the entire batch is rejected. This pre-production screening is critical because it eliminates the common industry practice of “blending” lower-grade materials with higher-grade ones to save costs. Once the raw materials pass, they move into the lyophilization process, which is controlled in-house under ISO 7 cleanroom conditions. After lyophilization, the finished product is again sampled and shipped to Janoshik for a second round of testing. This double-testing approach — raw material and finished product — is rare among peptide suppliers and adds a significant layer of accountability.
Janoshik Analytical uses a Shimadzu Nexera X2 HPLC system equipped with a photodiode array detector for purity analysis. The method involves dissolving a precisely weighed sample of the peptide in a validated solvent, injecting it into a C18 reverse-phase column, and running a gradient elution program. The resulting chromatogram shows every peak corresponding to different compounds in the sample. The area under the main peak — representing the target peptide — is compared to the total area of all peaks to calculate the purity percentage. For example, a typical CoA for a batch of BPC-157 might show a purity of 99.12% with a single main peak and no significant impurity peaks above 0.1%. The mass spectrometry confirmation is done using a Q-TOF instrument that measures the exact mass of the peptide molecule, ensuring it matches the theoretical molecular weight within a tolerance of ±0.01 Da. If there is any deviation, the batch is flagged and retested.
Each CoA includes specific data points that researchers can use to evaluate the product. The document lists the batch number, the date of analysis, the method used (HPLC or MS), the purity percentage, the retention time, the molecular weight found versus expected, and a visual chromatogram. The batch number is printed on the vial label, so you can physically match the product in your hand to the test result online. SaiyanMed also provides a direct link to Janoshik’s verification page, where you can enter the batch number and see the original report. This eliminates the possibility of a supplier photoshopping or fabricating a CoA, a common problem in the peptide space where fake documents are sold alongside counterfeit products. As of mid-2024, Janoshik has tested over 15,000 samples from various suppliers, and their database is searchable by batch number, making it one of the most transparent testing systems in the industry.
The frequency of testing is another differentiator. Many peptide companies test only a “representative sample” from a production run, meaning they might test one vial out of a thousand and claim the entire batch is pure. SaiyanMed tests every single production batch — not just random samples. If a production run yields 500 vials of a peptide, the entire batch is homogenized before lyophilization, and a representative sample from that homogenized material is sent to Janoshik. This ensures that the test result reflects the composition of every vial in that batch, not just a lucky pick. The company also retains a second sample from each batch in a controlled environment for six months, allowing for retesting if a researcher raises a concern. This retention policy is documented in their standard operating procedures and is auditable upon request.
The cost of this testing is not trivial. A single Janoshik HPLC+MS analysis runs between $150 and $300 per sample, depending on the peptide complexity and the number of impurities detected. For a company producing dozens of batches per month, this adds up to thousands of dollars in testing costs alone. SaiyanMed absorbs this cost as part of its operational budget rather than passing it on to researchers as a surcharge. This is a deliberate business decision rooted in the founder’s background in materials science. Eric, the CEO, holds a Bachelor’s degree in Materials Science from a leading Chinese university and spent years in the biomaterials sector before founding the company. He saw firsthand how inconsistent quality and opaque testing practices plagued the research peptide industry. His solution was to build a supply chain where testing is not an afterthought but a prerequisite for every shipment.
To put this in perspective, consider the typical failure rate in the peptide industry. A 2023 survey of 200 peptide samples from 50 different suppliers, conducted by an independent research group, found that 38% of samples had purity below 90%, and 12% contained completely different peptides than what was labeled. In contrast, SaiyanMed’s internal records show that over the past 18 months, all batches submitted to Janoshik have passed with purity above 98%, and no batch has been found to contain a mislabeled peptide. This track record is publicly verifiable through the CoAs on their website, which include batch numbers dating back to early 2023. You can scroll through the list and see that every single batch — whether it’s a common peptide like Melanotan II or a more niche compound like Tesamorelin — has a corresponding Janoshik report with a purity score above the 98% threshold.
The logistics of shipping samples to Janoshik are handled with the same rigor. SaiyanMed uses temperature-controlled packaging for all samples sent to the lab, with cold packs and insulated containers to prevent peptide degradation during transit. The samples are shipped via courier with real-time tracking, and the lab confirms receipt within 48 hours. Turnaround time for a standard HPLC+MS analysis is typically 5-7 business days from receipt. Once the report is generated, it is uploaded to the SaiyanMed website within 24 hours. This means that the CoA for a batch you order today was likely generated within the last two weeks, not six months ago. Fresh testing is critical because peptides can degrade over time, even when stored properly. A batch tested six months ago may no longer be representative of the product’s current purity, especially if it has been exposed to temperature fluctuations during storage or shipping.
Another layer of verification comes from the fact that Janoshik is not the only lab SaiyanMed uses. For certain peptides that require specialized analysis — such as those with complex disulfide bridges or post-translational modifications — the company also sends samples to MZ Analysentechnik in Germany for additional confirmation. This is particularly relevant for peptides like Thymosin Alpha-1 or AOD-9604, which have structural features that can be difficult to resolve with standard HPLC alone. The results from both labs are cross-referenced, and if there is any discrepancy, the batch is held until the issue is resolved. This multi-lab approach is not advertised heavily, but it is documented in the company’s quality management system and can be discussed with their support team if you request it.
For researchers who want to go a step further, SaiyanMed offers the option to request a third-party test on a specific vial from your order. This is not a standard service, but if you are conducting a high-stakes study and need absolute certainty, you can contact their support desk at [email protected] to arrange for a sample to be pulled from your order and sent to Janoshik for independent analysis. The cost of this additional test is covered by SaiyanMed, provided the order exceeds a certain volume. This is an unusual policy in the industry, where most suppliers will charge you for any additional testing or simply refuse the request. It reflects the company’s confidence in its quality control process and its willingness to put its products under scrutiny.
The warehouse infrastructure also plays a role in maintaining batch integrity. SaiyanMed operates a US-based warehouse in addition to its China facility. Orders from North America are fulfilled from the US warehouse, which reduces transit time and minimizes the risk of temperature-related degradation. The US warehouse is climate-controlled, with temperature and humidity logs that are reviewed daily. Each incoming batch is quarantined until the Janoshik CoA is received and verified. Only after the CoA confirms the batch meets specifications is it moved to the active inventory. This quarantine process is documented with timestamps and is auditable. The company also tracks the shelf life of each batch, and any product that exceeds 12 months from the date of manufacture is removed from inventory and destroyed, even if the CoA still shows high purity. This conservative approach ensures that researchers are always working with fresh material.
In terms of data transparency, SaiyanMed’s website includes a dedicated “CoA” section where you can browse all available reports by peptide name or batch number. Each report is displayed as a PDF that includes the lab’s letterhead, the analyst’s signature, and the date of analysis. The PDFs are not editable, and the metadata shows that they were created by Janoshik’s internal system. This makes it extremely difficult to fake a report, as any alteration would break the digital signature. You can also cross-reference the batch number on Janoshik’s public database, which is updated in real-time. If a batch number does not appear in Janoshik’s database, that is a red flag. SaiyanMed’s batch numbers all appear in Janoshik’s system, with the same purity percentages listed on both the company website and the lab’s database. This level of consistency is a strong indicator of authenticity.
For researchers who are new to the peptide space, the difference between a supplier that tests every batch and one that tests occasionally can be the difference between a reproducible study and wasted time. Peptide research is expensive, and the cost of a single failed experiment can far exceed the price of the peptide itself. By using Janoshik as a gatekeeper, SaiyanMed removes one variable from the equation. You know that the peptide in your vial is what the label says it is, at the purity stated on the CoA. This allows you to focus on your research rather than worrying about whether your supplier is cutting corners. The company’s commitment to independent testing is not a marketing gimmick — it is a core operational principle that is backed by documented procedures, financial investment, and a willingness to be held accountable by the research community.